A Phase IV Study of BMS-232632 in HIV+ Patients With Metabolic Syndrome

A Phase IV, One-arm, Open-label, Multicenter Study Evaluating Effect of Treatment Change to Atazanavir/Ritonavir on Brachial Endothelial Function of HIV Infected Patient Receiving Function in HIV Infected Patient Receiving Potent Antiretroviral Combination Therapy

The purpose of this clinical research study is to learn if BMS-232632 administered as Atazanavir/ritonavir (ATV/RTV) is superior to an anti-retroviral regimen including Lopinavir/ritonavir (LPV/RTV), as assessed by an increased brachial artery flow-mediated vasodilatation (FMD), in HIV-infected patients. The safety of this treatment will also be studied.

Inclusion Criteria:

- Documented Metabolic Syndrome by at least 3 of the following parameters:

• Abdominal obesity, assessed by waist circumference (for men >103 cm, for women >88 cm).
• Triglycerides > 150 mg/dl.
• HDL cholestrol (for men <40 mg/dl, for women <50 mg/dl).
• Blood pressure > or equal to 130/85 mm Hg.
• Fasting serum glucose > or equal to 110 mg/dl.
• HIV RNA < 50 copies/mL.
• IP within 3 months prior to selection.

Exclusion Criteria:

-Treated Metabolic Syndrom